Advertisement

Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan®) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients

  • Kai Johannes Lorenz
  • Heinz Maier
Head and Neck

Abstract

Photodynamic therapy (PDT) is a relatively new method of treating superficial tumours of the skin and mucosa. After the injection of a photosensitising agent, the tumour area is exposed to non-thermal laser light. This causes a phototoxic reaction, producing oxygen radicals that destroy tumour cells. From November 2003 to July 2007, a total of 35 patients with recurrent squamous cell carcinoma or secondary tumours of the head and neck region were treated with PDT at the German Armed Forces Hospital in Ulm. These patients had failed or found unsuitable for other treatments. Meta-tetrahydroxyphenylchlorin (mTHPC), known under the trade name of Foscan®, was used as the photosensitising agent. Local control was achieved in 21 patients (60%) and partial remission in 10 patients (28.5%). Four patients (11.5%) did not respond to PDT treatment. The mean duration of overall survival was 401.45 (±321.2) days, median was 356 after the completion of treatment. The mean duration of recurrence-free survival was 327.7 (±131.1) days, median was 181 for patients with complete remission. None of the patient developed serious complications. Photodynamic therapy is an important treatment option for patients who present with recurrent carcinoma or secondary tumours of the upper aerodigestive tract and who have failed or unsuitable for other treatments. Due to the excellent treatment results that have been achieved so far, PDT may in the future also play a role in the primary treatment of superficial tumours of the oral cavity, pharynx and larynx.

Keywords

Photodynamic therapy Foscan mTHPC Head and neck tumours Squamous cell carcinoma 

Notes

Conflicts of interest

We confirm that there are no financial contributions to the work and no potential conflicts of interest.

References

  1. 1.
    Betz CS, Leunig A (2004) Möglichkeiten und Grenzen der Fluoreszenzdiagnostik und photodynamischen Therapie. Teil II : Photodynamische Therapie. HNO 52:175–192. doi: 10.1007/s00106-003-1029-1 CrossRefPubMedGoogle Scholar
  2. 2.
    Biel MA (1994) Photodynamic therapy and the treatment of neoplastic diseases of the larynx. Laryngoscope 104:399–403. doi: 10.1288/00005537-199404000-00001 CrossRefPubMedGoogle Scholar
  3. 3.
    Biel MA (1996) Photodynamic therapy and the treatment of head and neck cancers. J Clin Laser Med Surg 14:239–244PubMedGoogle Scholar
  4. 4.
    Biel MA (1996) Photodynamic therapy as an adjuvant intraoperative treatment of recurrent head and neck carcinomas. Arch Otolaryngol Head Neck Surg 122:1261–1265PubMedGoogle Scholar
  5. 5.
    Blant SA, Glanzmann TM, Ballini JP, Wagnieres G, Van den Bergh H, Monnier P (2002) Uptake and localisation of mTHPC (Foscan) and its 14C-labelled form in normal and tumour tissues of the hamster squamous cell carcinoma model: a comparative study. Br J Cancer 87:1470–1478. doi: 10.1038/sj.bjc.6600651 CrossRefPubMedGoogle Scholar
  6. 6.
    Braichotte D, Savary JF, Glanzmann T et al (1995) Clinical pharmacokinetic studies of tetra(meta-hydroxyphenyl)chlorin in squamous cell carcinoma by fluorescence spectroscopy at 2 wavelengths. Int J Cancer 63:198–204. doi: 10.1002/ijc.2910630209 CrossRefPubMedGoogle Scholar
  7. 7.
    Carvalho AL, Salvajoli JV, Kowalski LP (2000) A comparison of radiotherapy or radiochemotherapy with symptomatic treatment alone in patients with advanced head and neck carcinomas. Eur Arch Otorhinolaryngol 257:164–167. doi: 10.1007/s004050050216 CrossRefPubMedGoogle Scholar
  8. 8.
    Copper MP, Tan IB, Oppelaar H, Ruevekamp MC, Stewart FA (2003) Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 129:709–711. doi: 10.1001/archotol.129.7.709 CrossRefPubMedGoogle Scholar
  9. 9.
    D’Cruz AK, Robinson MH, Biel MA (2004) mTHPC-mediated photodynamic therapy in patients with advanced incurable head and neck cancer: a multicenter study of 128 patients. Head Neck 26:232–240. doi: 10.1002/hed.10372 CrossRefPubMedGoogle Scholar
  10. 10.
    Dilkes MG, Alusi G, Djaezeri BJ (1999) The treatment of head and neck cancer with photodynamic therapy: clinical experience. Rev Contemp Pharmacother 10:47–57Google Scholar
  11. 11.
    Foote CS, Shook FC, Abakerli RB (1984) Characterization of singlet oxygen. Methods Enzymol 105:36–47. doi: 10.1016/S0076-6879(84)05006-0 CrossRefPubMedGoogle Scholar
  12. 12.
    Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer. N Engl J Med 345:1890–1900. doi: 10.1056/NEJMra001375 CrossRefPubMedGoogle Scholar
  13. 13.
    Forastiere A, Metch B, Schuller DE (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck. A Southwest Oncology Group study. J Clin Oncol 10:1245–1251PubMedGoogle Scholar
  14. 14.
    Galante E, Gallus G, Chiesa F, Bono A, Bettoni I, Molinari R (1982) Growth rate of head and neck tumors. Eur J Cancer Clin Oncol 18:707–712. doi: 10.1016/0277-5379(82)90067-0 CrossRefPubMedGoogle Scholar
  15. 15.
    Gedlicka C, Formaneck M, Selzer E, Burian M, Kornfehl J, Fiebiger W, Cartellieri M, Marks B, Kornek GV (2002) Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology 63:145–150. doi: 10.1159/000063809 CrossRefPubMedGoogle Scholar
  16. 16.
    Glanzmann C, Gratz KW (1995) Radionecrosis of the mandibula: a retrospective analysis of the incidence and risk factors. Radiother Oncol 36:94–100. doi: 10.1016/0167-8140(95)01583-3 CrossRefPubMedGoogle Scholar
  17. 17.
    Grant WE, Hopper C, Speight PM, MacRobert AJ, Bown SG (1993) Photodynamic therapy of malignant and premalignant lesions in patients with field cancerization of the oral cavity. J Laryngol Otol 107:1140–1145. doi: 10.1017/S0022215100125496 CrossRefPubMedGoogle Scholar
  18. 18.
    Hopper C, Niziolb C, Sidhub M (2004) The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral Oncol 40:372–382. doi: 10.1016/j.oraloncology.2003.09.003 CrossRefPubMedGoogle Scholar
  19. 19.
    Hopper C, Kübler A, Lewis H, Tan B, Putnam G (2004) mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer 111:138–146. doi: 10.1002/ijc.20209 CrossRefPubMedGoogle Scholar
  20. 20.
    Heimlich F, Dietz A, Daniel V, Maier H (1999) Einfluß tumorchirurgischer Eingriffe im Kopf-Hals-Bereich auf das Immunsystem. HNO 47:885–892. doi: 10.1007/s001060050529 CrossRefPubMedGoogle Scholar
  21. 21.
    Kramer S, Marcial VA, Pajak TF, MacLean CJ, Davis LW (1986) Prognostic factors for loco/regional control and metastasis and the impact on survival. Int J Radiat Oncol Biol Phys 12:573–578PubMedGoogle Scholar
  22. 22.
    Kübler AC, Scheer M, Zoller JE (2001) Photodynamic therapy of head and neck cancer. Onkologie 24:230–237. doi: 10.1159/000055085 CrossRefPubMedGoogle Scholar
  23. 23.
    Kübler A et al (2005) Eine Kosten-Effektivitätsanalyse der photodynamischen Therapie mit Foscan im Vergleich zur palliativen Chemotherapie bei Patienten mit fortgeschrittenen Kopf-Halstumoren in Deutschland. Laryngorhinootologie 84:1–8. doi: 10.1055/s-2005-861048 CrossRefGoogle Scholar
  24. 24.
    Maier H, Daniel V, Heimlich F, Frank C, Opelz G (1995) Zelluäre Immundefekte durch postoperative Bestrahlung bei Patienten mit Plattenepithelkarzinomen des oberen Aerodigestivtraktes. HNO 43:364–370PubMedGoogle Scholar
  25. 25.
    Moosmann P, Egli F, Stahel RA, Jost L (2003) Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie 26:568–572. doi: 10.1159/000074153 CrossRefPubMedGoogle Scholar
  26. 26.
    Nollert J, Rudat V, Daniel V, Maier H, Dietz A (1999) Einfluß der primären Radiochemotherapie auf zelluläre und subzelluläre immunologische Parameter. HNO 47:1058–1062. doi: 10.1007/s001060050491 CrossRefPubMedGoogle Scholar
  27. 27.
    Steel GG (1997) The growth rate of tumours. In: Steel G (ed) Basic clinical radiobiology, 2nd edn. Arnold, London, pp 9–13Google Scholar
  28. 28.
    The European Agency for the Evaluation of Medicinal Products (2001) Foscan: Summary of product characteristicsGoogle Scholar
  29. 29.
    Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 11:1116–1127. doi: 10.1056/NEJMoa0802656 CrossRefGoogle Scholar
  30. 30.
    Weymuller E, Alsarraf R, Yueh B, Deleyiannis F, Coltrera M (2001) Analysis of the performance characteristics of the University of Washington Quality of Life instrument and its modification (UW-QOL-R). Arch Otolaryngol Head Neck Surg 127(5):489–493PubMedGoogle Scholar
  31. 31.
    Wheeler RH (1990) Chemotherapy of patients with recurrent head and neck cancer. In: Jacobs C (ed) Carcinomas of the head and neck: evaluation and management. Kluwer, Boston, pp 171–193Google Scholar
  32. 32.
    Wong SJ, Machtay M, Li Y (2006) Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol 24:2653–2658. doi: 10.1200/JCO.2005.05.3850 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of Otolaryngology/Head and Neck SurgeryGerman Armed Forces Hospital of UlmUlmGermany

Personalised recommendations